Vincristine GLS 1mg Injection

About

Vincristine GLS 1mg Injection contains Vincristine, an antineoplastic agent belonging to the vinca alkaloid class, derived from the periwinkle plant. It exerts its cytotoxic effects by binding to tubulin, a protein essential for microtubule formation. This binding inhibits the polymerization of tubulin into microtubules, thereby disrupting the formation of the mitotic spindle apparatus. Consequently, cells are arrested in metaphase, preventing cell division and leading to apoptosis. Vincristine is cell-cycle specific, primarily affecting cells in the M phase of the cell cycle.

It is widely used in combination chemotherapy regimens for various cancers due to its efficacy and relatively mild myelosuppression compared to other chemotherapeutic agents. Its unique mechanism of action makes it a crucial component in protocols for hematological malignancies and solid tumors, particularly in pediatric oncology. Strict adherence to administration guidelines is vital, especially avoiding intrathecal administration, which is fatal.

Uses

• Treatment of acute lymphoblastic leukemia (ALL).
• Treatment of Hodgkin's and non-Hodgkin's lymphoma.
• Treatment of Wilms' tumor.
• Treatment of neuroblastoma.

Directions For Use

Administered intravenously by a healthcare professional, strictly avoiding intrathecal administration which is fatal.

Benefits

• Effective against a broad range of cancers.
• Often used in combination chemotherapy regimens.
• Relatively less myelosuppressive than other agents.
• Induces cell cycle arrest and apoptosis in cancer cells.
• Key component in pediatric oncology protocols.
• Contributes to improved survival rates in specific cancers.

Side Effects

• Peripheral neuropathy (paresthesia, weakness, foot drop).
• Constipation (common and potentially severe).
• Paralytic ileus.
• Jaw pain.
• Alopecia (hair loss).
• Hyponatremia (due to SIADH).
• Mild myelosuppression (leukopenia).
• Nausea and vomiting (less common).
• Orthostatic hypotension.
• Visual disturbances.
• Seizures.
• Injection site reactions (if extravasation occurs).

Safety Measures

• Alcohol - No specific contraindication, but avoid excessive alcohol due to potential for general health decline during chemotherapy.
• Pregnancy - Contraindicated in pregnancy due to teratogenic potential; effective contraception is essential.
• Breastfeeding - Not recommended during breastfeeding as it may be excreted in breast milk and harm the infant.
• Liver - Use with caution and dose reduction in patients with hepatic impairment due to altered metabolism and excretion.
• Kidney - Generally no dose adjustment needed for renal impairment, but monitor for potential neurotoxicity.
• Lung - No specific lung toxicity, but monitor for any unusual respiratory symptoms during treatment.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.